Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 30+ AI models, with 0% extra fees
Cooper Companies Stock: Is Wall Street Bullish or Bearish?
Cooper Companies Stock: Is Wall Street Bullish or Bearish?
Cooper Companies, Inc_ contacts-by JIPEN via Shutterstock
Neha Panjwani
Wed, February 18, 2026 at 9:42 PM GMT+9 2 min read
In this article:
COO
+1.06%
^GSPC
+0.92%
The Cooper Companies (COO), headquartered in San Ramon, California, develops, manufactures, and markets contact lens wearers. Valued at $16.3 billion by market cap, the company’s products include contact lenses for the vision care market and diagnostic products, surgical instruments, and accessories for gynecologists and obstetricians.
Shares of this global medical device company have underperformed the broader market over the past year. COO has declined 7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 11.9%. In 2026, COO stock is down marginally, aligning with SPX’s slight fall on a YTD basis.
More News from Barchart
Narrowing the focus, COO’s underperformance is also apparent compared to the SPDR S&P Health Care Equipment ETF (XHE). The exchange-traded fund has declined about 6.6% over the past year. However, the stock’s marginal losses on a YTD basis outshine the ETF’s 3.3% decline over the same time frame.
www.barchart.com
On Dec. 4, 2025, COO shares closed up more than 1% after reporting its Q4 results. Its revenue was $1.07 billion, surpassing analyst estimates of $1.06 billion. The company’s adjusted EPS of $1.15 beat analyst estimates by 3.2%.
For the current fiscal year, ending in October, analysts expect COO’s EPS to grow 9.5% to $4.51 on a diluted basis. The company’s earnings surprise history is impressive. It beat or matched the consensus estimate in each of the last four quarters.
Among the 18 analysts covering COO stock, the consensus is a “Moderate Buy.” That’s based on 10 “Strong Buy” ratings, one “Moderate Buy,” six “Holds,” and one “Strong Sell.”
www.barchart.com
This configuration is more bullish than a month ago, with nine analysts suggesting a “Strong Sell.”
On Feb. 3, Needham kept a “Buy” rating on COO and lowered the price target to $99, implying a potential upside of 20.8% from current levels.
The mean price target of $90.12 represents a 10% premium to COO’s current price levels. The Street-high price target of $100 suggests an upside potential of 22%.
_ On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com _
Terms and Privacy Policy
Privacy Dashboard
More Info